Status:
RECRUITING
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
CAR-T Therapy Complications
Eligibility:
All Genders
18-70 years
Brief Summary
The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of o...
Detailed Description
The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of o...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years. Patients with haematological pathology admitted to be subjected to CAR-T Therapy at the Advanced Cell Therapy Program, IRCCS University Hospital of Bologna.
- Patients who consent to participate in this study after signing informed consent.
Exclusion
- \-
Key Trial Info
Start Date :
May 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04892433
Start Date
May 14 2021
End Date
April 1 2026
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCC, University Hospital of Bologna
Bologna, Italy, Italy, 40138